Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes
Primary Purpose
Type2 Diabetes Mellitus
Status
Completed
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Glimepiride
Empagliflozin
Sponsored by

About this trial
This is an interventional treatment trial for Type2 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria:
- Age ≥19 years
- inadequate glycaemic control : HbA1c ≥6.5% or fasting glucose >120 mg/dl or random glucose >180 mg/dl
High risk of cardiovascular events defined as the presence of ≥1 of the following:
- History of myocardial infarction
- Evidence of multi-vessel coronary artery disease
- Evidence of single-vessel coronary artery disease with a positive non-invasive stress test for ischemia or history of hospitalization for unstable angina
- History of stroke
- Evidence of occlusive peripheral artery disease
- Evidence of carotid atherosclerosis
- Metabolic syndrome
- Healthy volunteers
Exclusion Criteria:
- Type 1 diabetes
- Organ transplantation
- Pregnant women
- eGFR <45
- Cortisol or growth hormone deficiency, pituitary diseases
- Gastric surgery
- Hematologic disorders
- Active cancers
Sites / Locations
- Yonsei University College of Medicine, Department of Internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes center
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Glimepiride
Empagliflozin
Arm Description
Glimepiride (anti-diabetic drug) as a comparison group
Empagliflozin (anti-diabetic drug) as a study group
Outcomes
Primary Outcome Measures
changes in the secretion of IL-1 beta from peripheral blood mononuclear cells
The effect of empagliflozin on the secretion of IL-1beta from peripheral blood mononuclear cells
Secondary Outcome Measures
Changes in the secretion of TNF-alpha from peripheral blood mononuclear cells, before and after the administration of empagliflozin or glimepiride
Changes in serum concentrations of beta-hydroxybutyrate, before and after the administration of empagliflozin or glimepiride
Changes in body weight (kg), before and after the administration of empagliflozin or glimepiride
Changes in serum concentrations of insulin (µU/mL), before and after the administration of empagliflozin or glimepiride
Changes in serum concentrations of glucagon (pg/mL), before and after the administration of empagliflozin or glimepiride
Changes in serum concentrations of free fatty acid (μEq/L), before and after the administration of empagliflozin or glimepiride
Changes in serum glycated albumin (%), before and after the administration of empagliflozin or glimepiride
Changes in serum concentrations of glucose (mg/dL), before and after the administration of empagliflozin or glimepiride
Changes in serum concentrations of uric acid (mg/dL), before and after the administration of empagliflozin or glimepiride
Changes in serum concentrations of liver enzymes (aspartate aminotransferase and alanine aminotransferase (IU/L)), before and after the administration of empagliflozin or glimepiride
Changes in serum lipids (total cholesterol, triglyceride, HDL cholesterol, and LDL cholesterol (mg/dL)), before and after the administration of empagliflozin or glimepiride
Changes in serum concentrations of creatinine (mg/dL), before and after the administration of empagliflozin or glimepiride
Changes in spot urine concentrations of glucose (mg/dL) and creatinine (mg/dL) (those will be combined to report spot urine glucose-to-creatinine ratio in mg/mg), before and after the administration of empagliflozin or glimepiride
Changes in mRNA expression level (PCR, fold) of IL-1beta, TNF-alpha, and NLRP3 in peripheral blood mononuclear cells, before and after the administration of empagliflozin or glimepiride
Changes in protein expression pattern (western blot, relative to control) of IL-1beta, TNF-alpha, and NLRP3 in peripheral blood mononuclear cells, before and after the administration of empagliflozin or glimepiride
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02964572
Brief Title
Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
August 2020
Overall Recruitment Status
Completed
Study Start Date
November 2016 (Actual)
Primary Completion Date
July 2017 (Actual)
Study Completion Date
July 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yonsei University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Single-center, prospective, active-controlled, open, randomized, 2 arm parallel, interventional, exploratory pilot
Type 2 diabetic patients with high cardiovascular risks who have inadequate glycaemic control with metformin-based oral hypoglycemic agents will be prescribed glimepiride (comparison group) or empagliflozin (study group) for 60 days (plus or minus 32 days) as add-on therapy
Changes in IL-1beta secretion, serum beta-hydroxybutyrate concentration, and NLRP3 inflammasome activity from baseline to final timepoint will be assessed.
Detailed Description
First among cardiovascular (CV) end point trials of glucose-lowering agents, the EMPA-REG OUTCOME trial-using 10 or 25 mg/day SGLT2 inhibitor empagliflozin against placebo in 7,020 patients with T2DM who were at increased CV risk-reported a 14% reduction in major CV events and marked relative risk reductions in CV mortality (38%), hospitalization for heart failure (35%), and death from any cause (32%) over a median time period of 2.6 years. Though these results have raised the possibility that mechanisms other than those observed in the trial-modest improvement in glycemic control, small decrease in body weight, and persistent reductions in blood pressure and uric acid level-may be at play, it's not clearly known yet.
The inflammatory nature of atherosclerosis is well established. We hypothesized that empagliflozin might have an inhibitory effect on inflammasome activity in macrophages, thus contribute to cardioprotective effects in diabetes.
Single-center, prospective, active-controlled, open, randomized, 2 arm parallel, interventional, exploratory pilot
Type 2 diabetic patients with high cardiovascular risks who have inadequate glycaemic control with metformin-based oral hypoglycemic agents will be prescribed glimepiride (comparison group) or empagliflozin (study group) for 60 days (plus or minus 32 days) as add-on therapy
Changes in IL-1beta secretion, serum beta-hydroxybutyrate concentration, and NLRP3 inflammasome activity from baseline to final timepoint will be assessed
Healthy volunteers : effect of 3 day-ketogenic diet on changes in cytokines, metabolites (IL-1beta, beta-hydroxybutyrate , etc) and inflammasome activity in macrophages
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type2 Diabetes Mellitus
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
61 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Glimepiride
Arm Type
Active Comparator
Arm Description
Glimepiride (anti-diabetic drug) as a comparison group
Arm Title
Empagliflozin
Arm Type
Experimental
Arm Description
Empagliflozin (anti-diabetic drug) as a study group
Intervention Type
Drug
Intervention Name(s)
Glimepiride
Other Intervention Name(s)
Amaryl
Intervention Description
In accordance with the standard treatment guidelines of diabetes, glimepiride as a drug of active comparator will be administered to improve blood sugar in patients with poorly controlled blood sugar.
Intervention Type
Drug
Intervention Name(s)
Empagliflozin
Other Intervention Name(s)
Jardiance
Intervention Description
Empagliflozin as a drug of experimental will be administered to improve blood sugar in patients with poorly controlled blood sugar.
Primary Outcome Measure Information:
Title
changes in the secretion of IL-1 beta from peripheral blood mononuclear cells
Description
The effect of empagliflozin on the secretion of IL-1beta from peripheral blood mononuclear cells
Time Frame
Day 60
Secondary Outcome Measure Information:
Title
Changes in the secretion of TNF-alpha from peripheral blood mononuclear cells, before and after the administration of empagliflozin or glimepiride
Time Frame
Day 60 plus or minus 32 days
Title
Changes in serum concentrations of beta-hydroxybutyrate, before and after the administration of empagliflozin or glimepiride
Time Frame
Day 60 plus or minus 32 days
Title
Changes in body weight (kg), before and after the administration of empagliflozin or glimepiride
Time Frame
Day 60 plus or minus 32 days
Title
Changes in serum concentrations of insulin (µU/mL), before and after the administration of empagliflozin or glimepiride
Time Frame
Day 60 plus or minus 32 days
Title
Changes in serum concentrations of glucagon (pg/mL), before and after the administration of empagliflozin or glimepiride
Time Frame
Day 60 plus or minus 32 days
Title
Changes in serum concentrations of free fatty acid (μEq/L), before and after the administration of empagliflozin or glimepiride
Time Frame
Day 60 plus or minus 32 days
Title
Changes in serum glycated albumin (%), before and after the administration of empagliflozin or glimepiride
Time Frame
Day 60 plus or minus 32 days
Title
Changes in serum concentrations of glucose (mg/dL), before and after the administration of empagliflozin or glimepiride
Time Frame
Day 60 plus or minus 32 days
Title
Changes in serum concentrations of uric acid (mg/dL), before and after the administration of empagliflozin or glimepiride
Time Frame
Day 60 plus or minus 32 days
Title
Changes in serum concentrations of liver enzymes (aspartate aminotransferase and alanine aminotransferase (IU/L)), before and after the administration of empagliflozin or glimepiride
Time Frame
Day 60 plus or minus 32 days
Title
Changes in serum lipids (total cholesterol, triglyceride, HDL cholesterol, and LDL cholesterol (mg/dL)), before and after the administration of empagliflozin or glimepiride
Time Frame
Day 60 plus or minus 32 days
Title
Changes in serum concentrations of creatinine (mg/dL), before and after the administration of empagliflozin or glimepiride
Time Frame
Day 60 plus or minus 32 days
Title
Changes in spot urine concentrations of glucose (mg/dL) and creatinine (mg/dL) (those will be combined to report spot urine glucose-to-creatinine ratio in mg/mg), before and after the administration of empagliflozin or glimepiride
Time Frame
Day 60 plus or minus 32 days
Title
Changes in mRNA expression level (PCR, fold) of IL-1beta, TNF-alpha, and NLRP3 in peripheral blood mononuclear cells, before and after the administration of empagliflozin or glimepiride
Time Frame
Day 60 plus or minus 32 days
Title
Changes in protein expression pattern (western blot, relative to control) of IL-1beta, TNF-alpha, and NLRP3 in peripheral blood mononuclear cells, before and after the administration of empagliflozin or glimepiride
Time Frame
Day 60 plus or minus 32 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Age ≥19 years
inadequate glycaemic control : HbA1c ≥6.5% or fasting glucose >120 mg/dl or random glucose >180 mg/dl
High risk of cardiovascular events defined as the presence of ≥1 of the following:
History of myocardial infarction
Evidence of multi-vessel coronary artery disease
Evidence of single-vessel coronary artery disease with a positive non-invasive stress test for ischemia or history of hospitalization for unstable angina
History of stroke
Evidence of occlusive peripheral artery disease
Evidence of carotid atherosclerosis
Metabolic syndrome
Healthy volunteers
Exclusion Criteria:
Type 1 diabetes
Organ transplantation
Pregnant women
eGFR <45
Cortisol or growth hormone deficiency, pituitary diseases
Gastric surgery
Hematologic disorders
Active cancers
Facility Information:
Facility Name
Yonsei University College of Medicine, Department of Internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes center
City
Seoul
ZIP/Postal Code
03722
Country
Korea, Republic of
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
35572519
Citation
Kim ER, Kim SR, Cho W, Lee SG, Kim SH, Kim JH, Choi E, Kim JH, Yu JW, Lee BW, Kang ES, Cha BS, Lee MS, Cho JW, Jeon JY, Lee YH. Short Term Isocaloric Ketogenic Diet Modulates NLRP3 Inflammasome Via B-hydroxybutyrate and Fibroblast Growth Factor 21. Front Immunol. 2022 Apr 28;13:843520. doi: 10.3389/fimmu.2022.843520. eCollection 2022.
Results Reference
derived
Learn more about this trial
Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes
We'll reach out to this number within 24 hrs